Cartesian Therapeutics, Inc. (RNAC) Tuesday announced positive updated data from the Phase 2b trial of Descartes-08 in people with myasthenia gravis (MG), an autoimmune disease that causes weakness in the voluntary muscles. The company's shares were up more than 5 percent in pre-market.
As previously announced, the trial had met its primary goal.
New data from the Phase 2b study showed that Descartes-08 provided deep and durable improvements over time for MG patients, with 5.5 reduction in MG Activities of Daily Living (MG-ADL) at Month 4. Durable responses were observed through Month 12, with 80 percent of participants showed a reduction in MG-ADL score of at least 2 points.
A Phase 3 study of Descartes-08, dubbed AURORA, is planned to begin in the first half of 2025.
Cartesian Therapeutics stock had closed at $19.57, up 3.93 percent on Monday. It has traded in the range of $11.66 - $41.87 in the last 1 year.
For comments and feedback: editorial@rttnews.com